Leukemia Clinical Trials in Beijing
26 recruitingBeijing, China
Showing 1–20 of 26 trials
Recruiting
Phase 3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled238 locationsNCT06852222
Recruiting
Phase 1Phase 2
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Acute Lymphocytic Leukemia
Chinese PLA General Hospital30 enrolled6 locationsNCT06481735
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Early Phase 1
Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
Leukemia
Beijing GoBroad Hospital3 enrolled1 locationNCT06890494
Recruiting
Phase 4
Asciminib Roll-over Study
Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals347 enrolled84 locationsNCT04877522
Recruiting
Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Hoffmann-La Roche137 enrolled31 locationsNCT05091424
Recruiting
Phase 3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Leukemia
Daiichi Sankyo700 enrolled292 locationsNCT06578247
Recruiting
Phase 2
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Lymphoma, Non-HodgkinB-cell LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Eli Lilly and Company13 enrolled6 locationsNCT07162181
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemias
Janssen Research & Development, LLC400 enrolled101 locationsNCT04811560
Recruiting
Phase 1
Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
Relapsed LeukemiaRefractory Leukemia
Beijing 302 Hospital5 enrolled1 locationNCT07297173
Recruiting
Phase 2
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Acute Myeloid LeukemiaLeukemia
Daiichi Sankyo130 enrolled58 locationsNCT06824168
Recruiting
Phase 3
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
Chronic Myelomonocytic Leukemia
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.170 enrolled43 locationsNCT06647862
Recruiting
Phase 1Phase 2
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Myeloid Leukemia, Philadelphia Positive
Novartis Pharmaceuticals44 enrolled40 locationsNCT04925479
Recruiting
Early Phase 1
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
AMLAML (Acute Myelogenous Leukemia)
Institute of Hematology & Blood Diseases Hospital, China10 enrolled1 locationNCT07126782
Recruiting
Phase 2
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Acute Myeloid Leukemia
Beijing 302 Hospital50 enrolled1 locationNCT07078591
Recruiting
Phase 2
Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT
Myelodysplastic SyndromeAcute Leukemia
Peking University People's Hospital40 enrolled1 locationNCT06984536
Recruiting
Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
LymphomaMDSLeukemia
Peking University First Hospital24 enrolled1 locationNCT06895538
Recruiting
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
Chronic Myeloid Leukemia
Peking University People's Hospital30 enrolled15 locationsNCT06390306
Recruiting
Phase 1
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.33 enrolled8 locationsNCT06927466
Recruiting
Phase 1
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
Acute Myeloid LeukemiaMyelodysplastic SyndromeB-cell Lymphoma
NovaOnco Therapeutics Co., Ltd.168 enrolled4 locationsNCT06820268